论文部分内容阅读
目的:探讨吗替麦考酚酯(MMF)与来氟米特治疗难治性肾脏综合征的疗效及安全性。方法:分别以吗替麦考酚酯与来氟米特治疗难治性肾病综合征均32例,随机分为治疗组和对照组。两组患者均采用强的松(起始剂量0.8mg/kg.d-1)治疗的基础上。在治疗前及治疗后第2、4、6、8、10及12周动态监测各项临床指标。比较12周的疗效及安全性。结果:MMF组24h尿蛋白较治疗前明显下降,血浆白蛋白在治疗后明显升高,完全缓解率为53.1%,总有效率78.1%。对照组24h尿蛋白与治疗组无差异性,完全缓解率为50%,总有效率71.9%,两组疗效相当。治疗组不良反应发生率均低于对照组。结论:吗替麦考酚酯治疗难治性肾病综合征的近期疗效较好,且不良反应少,耐受性好。
Objective: To investigate the efficacy and safety of mycophenolate mofetil (MMF) and leflunomide in the treatment of refractory renal syndrome. Methods: 32 cases of refractory nephrotic syndrome were treated with mycophenolate mofetil and leflunomide respectively, and were randomly divided into treatment group and control group. Both groups were based on prednisone (initial dose of 0.8 mg / kg.d-1). The clinical indexes were monitored dynamically before treatment and at the 2nd, 4th, 6th, 8th, 10th, and 12th week after treatment. Compare the efficacy and safety of 12 weeks. Results: 24 h urinary protein in MMF group was significantly lower than that before treatment, and plasma albumin increased significantly after treatment. The complete remission rate was 53.1% and the total effective rate was 78.1%. The control group 24h urinary protein and the treatment group no difference, the complete remission rate was 50%, the total effective rate 71.9%, the two groups had similar efficacy. Adverse reactions in the treatment group were lower than the control group. Conclusion: Mycophenolate mofetil treatment of refractory nephrotic syndrome has good short-term efficacy, with fewer adverse reactions and good tolerability.